Cargando…

Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study

Atopic dermatitis (AD) is a chronic, itchy skin condition that affects 15–20% of children but may occur at any age. It is estimated that 16.5 million US adults (7.3%) have AD that initially began at age >2 years, with nearly 40% affected by moderate or severe disease. Therefore, a quantitative me...

Descripción completa

Detalles Bibliográficos
Autores principales: Medela, Alfonso, Mac Carthy, Taig, Aguilar Robles, S. Andy, Chiesa-Estomba, Carlos M., Grimalt, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382656/
https://www.ncbi.nlm.nih.gov/pubmed/35990535
http://dx.doi.org/10.1016/j.xjidi.2022.100107
_version_ 1784769331200000000
author Medela, Alfonso
Mac Carthy, Taig
Aguilar Robles, S. Andy
Chiesa-Estomba, Carlos M.
Grimalt, Ramon
author_facet Medela, Alfonso
Mac Carthy, Taig
Aguilar Robles, S. Andy
Chiesa-Estomba, Carlos M.
Grimalt, Ramon
author_sort Medela, Alfonso
collection PubMed
description Atopic dermatitis (AD) is a chronic, itchy skin condition that affects 15–20% of children but may occur at any age. It is estimated that 16.5 million US adults (7.3%) have AD that initially began at age >2 years, with nearly 40% affected by moderate or severe disease. Therefore, a quantitative measurement that tracks the evolution of AD severity could be extremely useful in assessing patient evolution and therapeutic efficacy. Currently, SCOring Atopic Dermatitis (SCORAD) is the most frequently used measurement tool in clinical practice. However, SCORAD has the following disadvantages: (i) time consuming—calculating SCORAD usually takes about 7–10 minutes per patient, which poses a heavy burden on dermatologists and (ii) inconsistency—owing to the complexity of SCORAD calculation, even well-trained dermatologists could give different scores for the same case. In this study, we introduce the Automatic SCORAD, an automatic version of the SCORAD that deploys state-of-the-art convolutional neural networks that measure AD severity by analyzing skin lesion images. Overall, we have shown that Automatic SCORAD may prove to be a rapid and objective alternative method for the automatic assessment of AD, achieving results comparable with those of human expert assessment while reducing interobserver variability.
format Online
Article
Text
id pubmed-9382656
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93826562022-08-18 Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study Medela, Alfonso Mac Carthy, Taig Aguilar Robles, S. Andy Chiesa-Estomba, Carlos M. Grimalt, Ramon JID Innov Methods & New Technology Atopic dermatitis (AD) is a chronic, itchy skin condition that affects 15–20% of children but may occur at any age. It is estimated that 16.5 million US adults (7.3%) have AD that initially began at age >2 years, with nearly 40% affected by moderate or severe disease. Therefore, a quantitative measurement that tracks the evolution of AD severity could be extremely useful in assessing patient evolution and therapeutic efficacy. Currently, SCOring Atopic Dermatitis (SCORAD) is the most frequently used measurement tool in clinical practice. However, SCORAD has the following disadvantages: (i) time consuming—calculating SCORAD usually takes about 7–10 minutes per patient, which poses a heavy burden on dermatologists and (ii) inconsistency—owing to the complexity of SCORAD calculation, even well-trained dermatologists could give different scores for the same case. In this study, we introduce the Automatic SCORAD, an automatic version of the SCORAD that deploys state-of-the-art convolutional neural networks that measure AD severity by analyzing skin lesion images. Overall, we have shown that Automatic SCORAD may prove to be a rapid and objective alternative method for the automatic assessment of AD, achieving results comparable with those of human expert assessment while reducing interobserver variability. Elsevier 2022-02-11 /pmc/articles/PMC9382656/ /pubmed/35990535 http://dx.doi.org/10.1016/j.xjidi.2022.100107 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Methods & New Technology
Medela, Alfonso
Mac Carthy, Taig
Aguilar Robles, S. Andy
Chiesa-Estomba, Carlos M.
Grimalt, Ramon
Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study
title Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study
title_full Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study
title_fullStr Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study
title_full_unstemmed Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study
title_short Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study
title_sort automatic scoring of atopic dermatitis using deep learning: a pilot study
topic Methods & New Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382656/
https://www.ncbi.nlm.nih.gov/pubmed/35990535
http://dx.doi.org/10.1016/j.xjidi.2022.100107
work_keys_str_mv AT medelaalfonso automaticscoringofatopicdermatitisusingdeeplearningapilotstudy
AT maccarthytaig automaticscoringofatopicdermatitisusingdeeplearningapilotstudy
AT aguilarroblessandy automaticscoringofatopicdermatitisusingdeeplearningapilotstudy
AT chiesaestombacarlosm automaticscoringofatopicdermatitisusingdeeplearningapilotstudy
AT grimaltramon automaticscoringofatopicdermatitisusingdeeplearningapilotstudy